Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Cardiovasc Pharmacol ; 42(4): 573-80, 2003 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-14508245

RESUMO

The goal of this study was to determine how short-term (12 weeks) angiotensin type I (AT1) block begun late in life affects aspects of myocardial biology and physiologic function altered by normal aging. Exercise capacity, myocardial morphology, histopathology, and coronary vascular function (degree of coronary vasodilation in response to adenosine) were evaluated in 53 Fischer 344 rats. Adult (6 months of age) and old (21 months of age) rats were studied after 12 weeks of either control drinking water, a low dose of candesartan that did not significantly lower blood pressure (1 mg/kg/d), or a high dose of candesartan (10 mg/kg/d). Significant age-associated changes in exercise capacity (38% decrease), coronary dilation in response to adenosine (41% decrease), and histopathology occurred but were not affected by candesartan treatment. Age-associated myocardial hypertrophy occurred as indicated by an increase in heart weight-to-tibia length ratio from 0.27 g/cm +/- 0.01 in the adult controls to 0.34 g/cm +/- 0.02 in the old controls (P < 0.05). This hypertrophy in the aged hearts was significantly attenuated by both low-dose (0.30 g/cm +/- 0.01) and high-dose (0.29 g/cm +/- 0.01) candesartan (P < 0.05). Echocardiographic measurements indicate that the candesartan-induced decrease in hypertrophy occurred concomitantly with slight decreases in septal wall thickness and left ventricular (LV) chamber diameter. It is concluded that short-term AT1 block, even when initiated late in life, can decrease age-associated LV hypertrophy independent of blood pressure-lowering effects.


Assuntos
Bloqueadores do Receptor Tipo 1 de Angiotensina II , Benzimidazóis/farmacocinética , Compostos de Bifenilo/farmacocinética , Coração/efeitos dos fármacos , Coração/fisiologia , Tetrazóis , Adenosina/administração & dosagem , Adenosina/farmacocinética , Envelhecimento/efeitos dos fármacos , Animais , Benzimidazóis/administração & dosagem , Compostos de Bifenilo/administração & dosagem , Pressão Sanguínea/efeitos dos fármacos , Pressão Sanguínea/fisiologia , Peso Corporal/efeitos dos fármacos , Vasos Coronários/efeitos dos fármacos , Vasos Coronários/fisiologia , Tolerância ao Exercício/efeitos dos fármacos , Coração/anatomia & histologia , Hipertrofia Ventricular Esquerda/tratamento farmacológico , Hipertrofia Ventricular Esquerda/patologia , Músculo Liso Vascular/efeitos dos fármacos , Miocárdio/patologia , Tamanho do Órgão/efeitos dos fármacos , Ratos , Ratos Endogâmicos F344 , Receptor Tipo 1 de Angiotensina/efeitos dos fármacos , Tíbia/anatomia & histologia , Resistência Vascular/efeitos dos fármacos , Resistência Vascular/fisiologia , Vasodilatação/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...